US reciprocal tariffs weigh on India, analysts say

Published 03/04/2025, 19:02
© Reuters

Investing.com -- U.S. President Trump’s sweeping move to impose reciprocal tariffs on all trading partners, with India facing a 27% duty on its exports, has prompted a mixed reaction from market strategists, who see both insulation and emerging risks for the South Asian economy.

BofA said India appears relatively well positioned amid the tariff escalation. India contributes only $47 billion, or 4% of the U.S. trade deficit, and its exports to the U.S. account for just 2% of GDP.

This makes India competitive relative to emerging market peers facing tariffs as high as 46% on exports to Washington.

Indian goods exports to the U.S. in calendar year 2024 totaled $80.7 billion, with tariff exemptions covering 279 items valued at around US$5-8 billion.

However, the direct impact, estimated at a worst-case scenario of about $20 billion or less than 50 basis points of India’s GDP, may only be part of the story.

There is a potential cascading effect: lower import tariffs that could dent domestic manufacturing and $28 billion in import tax collections, delayed capital expenditure decisions, slower credit growth, and a widening trade gap if India increases imports from the U.S.

These risks, coupled with a broader environment of global trade uncertainty, could weigh on currencies and prompt a flight from equities.

Jefferies echoed a cautious tone, highlighting that while the headline tariff of 27% on India is moderate compared to higher tariffs imposed on countries like Vietnam and Thailand, the broader U.S. economic outlook presents challenges.

The firm noted that key export sectors, notably IT, pharmaceuticals, and autos, should experience limited direct impact.

India’s software exports, valued at $103 billion in FY24, remain unaffected, and the pharma industry is temporarily exempt from tariffs.

Analysts expect a potential rally in U.S.-focused generic pharma stocks, naming companies such as Lupin (NSE:LUPN), Dr Reddy’s, and Zydus as best positioned for the near term.

In the IT sector, despite no direct hit from the tariff order, there are concerns over indirect repercussions from a slower U.S. GDP growth rate.

While on-shoring and tighter immigration norms could pressure margins, recalling the previous tightening of the H1B visa regime, major players like Tech Mahindra (NSE:TEML) and HCLTech, as well as mid-cap firms with favorable vertical exposure, appear better positioned to withstand these challenges.

Sector-specific risks extend beyond technology and pharmaceuticals. In autos, companies with high U.S. export exposure, including certain OEMs and auto component makers, are likely to feel the pressure, as are chemicals and solar sectors.

Firms such as Navin Fluorine, PI Industries, and solar specialist Waaree could face significant headwinds, with the latter also subject to an additional 14.5% customs duty.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.